Q-omics provides the consensus-scored LMO7DN profile across patient tissues and cancer cell-line models. LMO7DN expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LMO7DN is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, LMO7DN RNA expression shows 10,335 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUSC, and TGCT as cancer lineages where LMO7DN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMO7DN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMO7DN survival associations across molecular data types. LMO7DN RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMO7DN RNA expression–survival associations across cancer types. High LMO7DN expression shows unfavorable associations in ACC, KIRC, LGG and BLCA, but favorable associations in LUAD and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LMO7DN RNA expression.
This table summarizes LMO7DN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LMO7DN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMO7DN shows lower tumor expression in LUSC, LUAD, HNSC, BRCA, KICH and KIRC. The LUSC box plot shows higher LMO7DN RNA expression in normal versus tumor tissue (log2 FC = −0.694, t-test p < 0.001).
This table shows molecular features associated with LMO7DN in patient tissues and cancer cell lines. In patient samples, LMO7DN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
